Findings

What do systematic reviews say?

324 questions · 341 findings · 54 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 120 · 35.2%GRADE not reported 9 · 2.6%Very low 97 · 28.4%Low 80 · 23.5%Moderate 25 · 7.3%High 10 · 2.9%

Methotrexate vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate and anti‐T lymphocyte immunoglobulin vs methotrexate

Change in muscle mass at 12 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate and azathioprine vs methotrexate (plus leucovorin)

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IVIg vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oxandrolone vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported

Interferon beta‐1a vs placebo

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 58 participants
Moderate

Intervention not reported

Body mass index, change from baseline (kg/m2) · people with primary prevention of cardiovascular disease in

1 finding from 1 review

Multiple risk factor interventions for primary prevention of cardiovascular disease in low‐ and middle‐income countries 2015 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 2984 participants
Low

Balanced nutritional supplement vs counselling or nutritional placebo

Fat mass measured in % of TBW · patients with reducing morbidity and mortality in people with HIV

1 finding from 1 review

Nutritional interventions for reducing morbidity and mortality in people with HIV 2013 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 233 participants
Moderate

Balanced nutritional supplement vs counselling or nutritional placebo

Fat free mass · patients with reducing morbidity and mortality in people with HIV

1 finding from 1 review

Nutritional interventions for reducing morbidity and mortality in people with HIV 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 218 participants
Low

Intervention not reported

Fat‐free mass/fat‐free mass index (change from baseline; mixed population) kg/m2 · patients with stable chronic obstructive pulmonary disease

1 finding from 1 review

Nutritional supplementation for stable chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 287 participants
Low

Intervention not reported

Fat‐free mass/fat‐free mass index (change from baseline; undernourished participants) kg/m2 · patients with stable chronic obstructive pulmonary disease

1 finding from 1 review

Nutritional supplementation for stable chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 125 participants
Low

Intervention not reported

Fat mass/fat mass index (change from baseline; undernourished participants) kg/m2 · patients with stable chronic obstructive pulmonary disease

1 finding from 1 review

Nutritional supplementation for stable chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 91 participants
Moderate

Intervention not reported

Fat‐free mass index (mixed population) kg/m2 · patients with stable chronic obstructive pulmonary disease

1 finding from 1 review

Nutritional supplementation for stable chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 93 participants
Low

Intervention not reported

Fat‐free mass index (undernourished patients) kg/m2 · patients with stable chronic obstructive pulmonary disease

1 finding from 1 review

Nutritional supplementation for stable chronic obstructive pulmonary disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 62 participants
Low

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
GRADE not reported

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE

It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
OR 0.31 [0.01, 7.96]
1 study · 59 participants
Very low

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

Treatment‐associated major haemorrhage ( · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
GRADE not reported

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

Treatment‐associated minor haemorrhage ( · people with intermediate‐risk (submassive) APE

It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes treatment‐associated minor haemorrhage ( compared with standard intravenous heparinisation (very low certainty).

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
OR 3.11 [0.3, 31.79]
1 study · 59 participants
Very low

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

Recurrent APE requiring retreatment or change to a different APE treatment ( · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
GRADE not reported

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

Length of hospital stay · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low